- Home
- LRE vs IPA Comparison
LRE vs IPA Comparison
Compare LRE & IPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- IPA
- Stock Information
- Founded
- LRE 2001
- IPA 1983
- Country
- LRE Japan
- IPA Canada
- Employees
- LRE N/A
- IPA N/A
- Industry
- LRE
- IPA Biotechnology: Pharmaceutical Preparations
- Sector
- LRE
- IPA Health Care
- Exchange
- LRE Nasdaq
- IPA Nasdaq
- Market Cap
- LRE 18.3M
- IPA 19.3M
- IPO Year
- LRE 2023
- IPA 2017
- Fundamental
- Price
- LRE $1.25
- IPA $0.38
- Analyst Decision
- LRE
- IPA Strong Buy
- Analyst Count
- LRE 0
- IPA 2
- Target Price
- LRE N/A
- IPA $4.00
- AVG Volume (30 Days)
- LRE 2.6K
- IPA 2.3M
- Earning Date
- LRE 01-01-0001
- IPA 03-28-2025
- Dividend Yield
- LRE N/A
- IPA N/A
- EPS Growth
- LRE N/A
- IPA N/A
- EPS
- LRE 0.29
- IPA N/A
- Revenue
- LRE $117,804,154.00
- IPA $16,581,105.00
- Revenue This Year
- LRE N/A
- IPA $1.88
- Revenue Next Year
- LRE N/A
- IPA $9.90
- P/E Ratio
- LRE $4.20
- IPA N/A
- Revenue Growth
- LRE 8.82
- IPA 1.35
- 52 Week Low
- LRE $1.10
- IPA $0.27
- 52 Week High
- LRE $13.76
- IPA $1.50
- Technical
- Relative Strength Index (RSI)
- LRE 50.02
- IPA 44.80
- Support Level
- LRE $1.19
- IPA $0.32
- Resistance Level
- LRE $1.26
- IPA $0.46
- Average True Range (ATR)
- LRE 0.04
- IPA 0.05
- MACD
- LRE 0.03
- IPA -0.00
- Stochastic Oscillator
- LRE 82.37
- IPA 42.70
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.